Quebec Makes It Harder to Use Originator Biologics
Biosimilars were on formulary for years but nobody was using them, Canadian authorities explain as their reasons for dropping originators from approved lists.
AbbVie's Gonzalez Is on Defense as House Members Petition FTC
Accused of unfair trade practices, AbbVie's CEO Richard Gonzalez pointed the finger at Medicare Part D.
Kaiser Permanente Investigators Confirm Mvasi Safety and Efficacy in Population With Nonsquamous NSCLC
The retrospective, real-world study (N = 353) conducted within the Kaiser Permanente network followed the July 2019 launch of the bevacizumab biosimilar Mvasi.
House Committee Issues Blistering Report on AbbVie's Humira Tactics
The House Committee on Oversight and Reform contends AbbVie's "biosimilar defense strategy" has succeeded beyond the company's wildest imagination.
Sandoz Is 0-3 in Enbrel Patent Case
Originator company Amgen has won another round in defending its lucrative etanercept franchise, but the decision is sure to intensify scrutiny of extended patent protections.
German Study Calculates Adalimumab Biosimilar Savings From Earlier Intervention
Investigators evaluated both biosimilar vs originator savings and savings from earlier use of a lower-cost adalimumab biosimilar (Amgevita).
Biosimilars News Roundup: BLA Tailoring, Medicare 5-Star Ratings
Streamlining of biologics license applications (BLAs) in Britain is now official, and in the United States, legislators propose a ratings system to promote biosimilars.
Study: Grastofil Equivalence Confirmed in ASCT Setting
A Canada study of the filgrastim biosimilar Grastofil demonstrated equivalence to Neupogen in candidates for autologous stem cell transplantation (ASCT), an extrapolated use.
The Top 5 Biosimilar Articles for the Week of May 10
Here are the top 5 biosimilar articles for the week of May 10, 2021.
Samsung Bioepis Executive Reflects on Interchangeable Designation
A second class of biosimilars that are considered "interchangeable" could set biosimilars back in terms of acceptance, according to Albert Kim, MBA.
Coherus Aims to Chip Away at Onpro Dominance
With COVID-19 on the retreat, Coherus BioSciences sees the advantage wearing off for Amgen's pegfilgrastim injector kit.
Poll: Where Do You Stand on Product Exclusivity Protections?
When it comes to biologics, there is a constant push and pull over patent rights. Some believe this is part of a healthy market-driven economy. Others are skeptical.
Alvotech Files Suit to Invalidate Humira Patents
After being sued for allegedly stealing adalimumab process information, Alvotech fires back.
Inflectra Stands Out in Meta-analysis of Agents for Crohn Disease
Investigators ranked biologics and Janus kinase 1 inhibitors based on past findings.
US, EU Regulators Discuss Tailoring Biosimilar Approvals
During a talk at the Medicines for Europe Biosimilar Medicines Conference, US and EU regulators discuss the potential for tailored approach to bring biosimilars to market sooner with less expense and wasted effort.
Not So Different: The Fight to Align Payer Preferences With Community Oncology
This is the third and final part of our series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.
Opinion: Purple Book Patent Listings Are Only a First Step
Intellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.
Regulators Look Back on 15 Years of Biosimilars in Europe
Advances in analytical testing have improved confidence in biosimilars, according to a Medicines for Europe panel.
The Top 5 Biosimilar Articles for the Week of May 3
Here are the top 5 biosimilar articles for the week of May 3, 2021.
Maria Manley Discusses the Consequences of Brexit for the Pharmaceutical Industry
Maria Manley, LLM, a life sciences expert and London-based partner with Sidley Austin, provides a deep-dive look at the complexities of Brexit and how it is likely to challenge the biologics industry.
Pfizer and Organon Provide a Glimpse of Biosimilars Strategy
Pfizer doubles down on its pledge to fight rebates, and Organon executives discuss the growth potential of this planned Merck spinoff.
The Difference Between an Interchangeable Biosimilar and One That Isn't
The anatomy of an interchangeability switching study.
Amgen Canada Launches Adalimumab Biosimilar
Amgevita is now broadly available across Canada.
Biosimilar Business Roundup for April 2021
Biosimilar companies partnered with other companies and saw earnings increases, while reference product corporations faced sales erosion from biosimilar competition.
Sandoz to Start Phase 3 Trial of Aflibercept Biosimilar
There are multiple contenders now in the race to bring the first aflibercept (Eylea) biosimilar to market in the United States and European Union.
AbbVie CEO Is on Deck as Antitrust Hearings Heat Up
Representative Carolyn B. Maloney, D-New York, questions the use of pharmaceutical profits to defend against biosimilar competition.
Reports From Biocon, Celltrion on Finances, COVID-19 Treatments
Biocon tests the waters with itolizumab in pandemic-ravaged India, and Celltrion announces early success with an agent for the South African variant.
Amgen, Merck, Teva Provide First-Quarter Biosimilars Info
There's no end in sight for Enbrel (etanercept) sales erosion, but Amgen's biosimilars are holding their own, the company reported.
The Top 5 Biosimilar Articles for the Week of April 26
Here are the top 5 biosimilar articles for the week of April 26, 2021.
Cyltezo Is a Contender for First Interchangeable to Humira, Boehringer Ingelheim Says
The results of Voltaire-X could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.